Young Jeffrey E 4
4 · JUNIPER PHARMACEUTICALS INC · Filed Aug 15, 2018
Insider Transaction Report
Form 4
Young Jeffrey E
Chief Financial Officer
Transactions
- Disposition to Issuer
Common Stock
2018-08-14$11.50/sh−30,413$349,750→ 0 total - Disposition to Issuer
Employee Stock Option (right to buy)
2018-08-14−40,000→ 0 totalExercise: $7.90Exp: 2025-02-09→ Common Stock (40,000 underlying) - Disposition to Issuer
Nonqualified Stock Option (right to buy)
2018-08-14−170,000→ 0 totalExercise: $5.60Exp: 2024-01-03→ Common Stock (170,000 underlying)
Footnotes (3)
- [F1]Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement") among Catalent Pharma Solutions, Inc., Catalent Boston, Inc. and Juniper Pharmaceuticals Inc. (the "Issuer") dated as of July 2, 2018. At the effective time of the merger (the "Effective Time") as contemplated in the Merger Agreement, each share of outstanding Issuer common stock (other than appraisal shares and certain other shares), and each outstanding and unexercised Issuer stock option (whether vested or unvested) and each outstanding unvested restricted stock unit, immediately prior to the Effective Time were cancelled in exchange for $11.50 per share, net in cash, without interest, less any applicable taxes and applicable exercise price for the stock option (the "Offer Price").
- [F2]Includes 27,150 restricted stock units that did not vest prior to the Effective Time of the merger. Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unvested 27,150 restricted stock units was cancelled in exchange for the Offer Price.
- [F3]Pursuant to the Merger Agreement, at the Effective Time, each of the outstanding and unexercised Issuer stock options (whether vested or unvested) was cancelled in exchange for cash equal to the product of (i) the excess of the Offer Price over the exercise price of the option and (ii) shares issuable upon exercise of the outstanding stock options.